Reports Q2 revenue $415M, consensus $458.57M. “This is an exciting time for Novavax, and we have been keenly focused on evolving our operating model to leverage our key drivers of value,” said CEO John Jacobs. “We intend to drive future value for the business through not only the Sanofi partnership, but also through our late-stage combination and influenza assets. We plan to unveil a new and expanded clinical pipeline by the end of this year and leverage both the pipeline and our proven technology to drive additional partnerships and deals and to ultimately drive significant, long-term value for our shareholders.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights
- Novavax (NVAX) Q2 Earnings Cheat Sheet
- Affirm, Sprouts Farmers upgraded: Wall Street’s top analyst calls
- Novavax downgraded to Underweight from Neutral at JPMorgan
- Novavax call volume above normal and directionally bullish
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue